Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling ...

WuXi Biologics & Virogen Biotechnology establish commercial manufacturing partnership: Chengdu Tuesday, June 10, 2025, 17:00 Hrs [IST] WuXi Biologics, a leading global contract research, development, ...

The state-of-the-art facilities will feature WuXi Biologics’ recently launched microbial expression platform EffiX for the development and manufacturing of biologics with high yield, consistent ...

CHENGDU, China, June 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked ...

After delivering strong sales growth last year and with more expansion in mind, CDMO giant Wuxi Biologics is breaking ground on a new microbial production plant in Chengdu, China. The 95,000 ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked off construction of its new microbial ...

HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025. MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: ...

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

The strategic collaboration includes an exchange of Agenus’ state-of-the-art biologics CMC facilities in Emeryville, CA and Berkeley, CA for upfront consideration of $75M; Agenus to receive up to an ...